Clinical Trial Update: A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating SEP-363856 (ulotaront) for schizophrenia in patients switching from their current antipsychotic has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• SEP-363856

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2025-11-12